Heterogeneity in COVID-19 Convalescent Plasma Clinical Trials

Due to the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, clinical trial (CT) research for efficacy and safety evaluation of convalescent plasma (CP) accelerated globally. In trial planning and approval, clinical researcher and regulatory agencies worldwide are challenged by limited evidence from the use of convalescent plasma in previous outbreaks of viral diseases and by different possible study approaches. We analyzed CT designs to identify potential opportunities for data aggregation and to facilitate generation of decision-relevant evidence.